Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)

NCT00733135 is registered in ClinicalTrials.gov with Medtronic Endovascular as lead sponsor.

NCT NCT00733135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00733135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)
Lead sponsor
Medtronic Endovascular
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2008
Completion date
November 30, 2010
Enrollment
133 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial disease